123 related articles for article (PubMed ID: 12560937)
1. Granisetron: relating pharmacology to clinical efficacy.
Blower PR
Support Care Cancer; 2003 Feb; 11(2):93-100. PubMed ID: 12560937
[TBL] [Abstract][Full Text] [Related]
2. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
3. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
4. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Goldsmith B
Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
[No Abstract] [Full Text] [Related]
5. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
[TBL] [Abstract][Full Text] [Related]
6. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
Feyer P; Seegenschmiedt MH; Steingraeber M
Support Care Cancer; 2005 Sep; 13(9):671-8. PubMed ID: 16044252
[TBL] [Abstract][Full Text] [Related]
7. Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability.
Prentice HG
Support Care Cancer; 2003 Aug; 11(8):501-8. PubMed ID: 12845514
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of granisetron for cancer patients undergoing platinum-based chemotherapy: comparison of 1 miligram versus 3 miligram doses in preventing nausea and vomiting.
Kurnianda J; Hisyam B; Wahyuningsih E; Hutajulu SH
Acta Med Indones; 2005; 37(4):210-3. PubMed ID: 16317218
[TBL] [Abstract][Full Text] [Related]
9. Re: Peter Blower's recent review of granisetron.
Russo M
Support Care Cancer; 2004 Jan; 12(1):64-5; author reply 66-8. PubMed ID: 14673627
[No Abstract] [Full Text] [Related]
10. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
11. [Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study].
Golaszewski T; Kölbl H; Lahousen M; Staab HJ
Wien Klin Wochenschr; 1995; 107(20):613-21. PubMed ID: 7502509
[TBL] [Abstract][Full Text] [Related]
12. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Okamoto S; Takahashi S; Tanosaki R; Sakamaki H; Onozawa Y; Oh H; Miyawaki S; Kimura Y; Toyama K; Ikeda Y; Asano S
Bone Marrow Transplant; 1996 May; 17(5):679-83. PubMed ID: 8733681
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
15. [Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses].
Mabro M; Cohn R; Zanesco L; Madon E; Hahlen K; Margueritte G; Breatnach F; Gentet JC; Plouvier é
Bull Cancer; 2000 Mar; 87(3):259-64. PubMed ID: 10779814
[TBL] [Abstract][Full Text] [Related]
16. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
17. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
[TBL] [Abstract][Full Text] [Related]
18. [The use of granisetron per os in radiotherapy-induced emesis].
Krengli M; Lazzari R; Manara M
Minerva Med; 1996 Dec; 87(12):605-8. PubMed ID: 9064597
[TBL] [Abstract][Full Text] [Related]
19. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
[TBL] [Abstract][Full Text] [Related]
20. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
